FINWIRES · TerminalLIVE
FINWIRES

$MRNA

48 stories mentioning MRNAUpdated 17d ago

Every FINWIRES story that references MRNA, newest first.

Sectors

Sector Update: Health Care Stocks Lower Early Monday

Healthcare stocks were mixed in early trading Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down by 0.2% and the iShares Biotechnology ETF (IBB) 1.4% lower.Moderna (MRNA) shares fell 1.2%, extending the 10.8% loss in the previous session. Jefferies lifted its price target on the company to $60 from $53, while maintaining a hold rating.Madrigal Pharmaceuticals (MDGL) traded down 0.5% after a 4.2% fall at the end of Friday's session. The company said that the US Patent and Trademark Office has issued three new patents covering resmetirom, strengthening its intellectual property portfolio for Rezdiffra.InMode (INMD) stock was down more than 1% after rising 1.8% at the prior close. The company reported preliminary Q2 revenue of $95.2 million to $95.4 million.

$IBB$INMD$MDGL$MRNA$XLV
Asia Markets

Update: US Equity Indexes Rise as Diplomatic Engagements Between Washington, Iran Send Crude Oil Lower

(Updates with index/price moves and company/geopolitical news from the first paragraph.)US equity indexes rose amid a broad-based rally as crude oil extended declines after Washington replaced air strikes on Iran with diplomatic engagements.The Nasdaq Composite edged up 0.3% to 26,281.61, with the Dow Jones Industrial Average up 0.3% to 52,637.01 and the S&P 500 higher by 0.4% to 7,575.39 on Friday. All but one sector, healthcare, rose. Materials led the gainers.The CBOE Volatility Index, also known as the fear gauge, dropped 5.1% to 15.03.Talks between the US and Iran over a permanent peace deal are continuing, Bloomberg reported, citing an American official. The US is still committed to finding a diplomatic solution with Iran, the official told Bloomberg on Thursday. The official described the ongoing discussions as technical talks.Iran had asked to continue talks, and the US agreed, but the June ceasefire is "over," President Donald Trump said in a Truth Social post."The US has said that progress on the MoU is 'performance-based', and therefore, as long as Iran moves forward with a certain behaviour such as allowing the right of passage through the Strait of Hormuz, the US will move forward with what was promised to Iran," Al Jazeera, a Middle Eastern broadcaster, reported Friday, citing Dania Thafer, executive director at Gulf International Forum.At least 15 commercial vessels transited the Strait of Hormuz in the past 24 hours, CNN reported, citing MarineTraffic data.The front-month global benchmark North Sea Brent slipped 0.4% to $76.02 a barrel, while the US West Texas Intermediate retreated 0.7% to $71.56 a barrel, extending declines from Thursday.Most US Treasury yields rose, with the 10-year up 1.8 basis points to 4.56% and the two-year climbing 4.6 basis points to 4.21% as investors watched geopolitical developments and awaited the consumer price index data for June next week, as the June 16-17 meeting of the Federal Open Market Committee showed widespread disagreement among participants in relation to inflationary pressures.In precious metal markets, gold futures fell 0.5% to $4,119.4, and silver futures declined 1% to $60.16.In company news, SK Hynix (SKHY, SKHYV) jumped 13% after listing its American depositary receipts on Nasdaq, with trading volume exceeding 105.8 million.Shares of Meta Platforms (META) jumped almost 6%, the top gainer on the S&P 500 and the Nasdaq, after a Bloomberg report cited Chief Executive Mark Zuckerberg as saying the company is considering renting out some of its artificial intelligence compute as demand for AI infrastructure surges.Moderna (MRNA) was the worst performer on the S&P 500, down nearly 11%.

Dow JonesNasdaq CompositeS&P 500$META$MRNA$SKHY$SKHYV
Update: US Equities Rise, Oil Prices Ease as Trump Confirms Iran Talks
US Markets

Update: US Equities Rise, Oil Prices Ease as Trump Confirms Iran Talks

(Updates with market moves at the end of the day and weekly index changes.)US equities rose Friday, rebounding at the end of a mixed week on Wall Street, while oil prices slipped as President Donald Trump confirmed talks with Iran.The S&P 500 rose 0.4% to 7,575.4. The Dow Jones Industrial Average and the Nasdaq Composite added 0.3% each to close at 52,637 and 26,281.6, respectively. Health care was the sole laggard among sectors, while materials led gainers.The Nasdaq and the S&P 500 logged their second consecutive weekly gains, advancing 1.7% and 1.2%, respectively. The Dow edged down 0.5% from last week after a run of four weekly wins.West Texas Intermediate crude oil was down 0.7% at $71.60 per barrel in Friday late-afternoon trade, while Brent ticked down 0.3% to $76.06.US crude futures were on track for their first weekly advance following four consecutive weekly declines. Brent prices were headed for their second straight weekly rise.Trump said Friday that the US agreed to continue negotiations with Iran, although he reiterated that their ceasefire is over.Hostilities between the two countries resumed in recent days, weeks after they reached an interim agreement to end their war.Qatari negotiators travelled to Iran, seeking to de-escalate the situation in a trip that was planned in coordination with the US, CNN reported Friday, citing a diplomat with knowledge of the visit."With oil prices softening following the mid-week spike, traders appear to view the latest tensions as a challenge to the ceasefire rather than a complete breakdown," Saxo Bank said in a report Friday. "Traffic through the Strait of Hormuz remains low, with no large commodity-laden vessels seen transiting."The International Energy Agency on Friday projected a smaller decline in global oil demand in 2026 amid signs of a rebound in consumption as crude flows improve.US Treasury yields were higher, with the two-year rate up 4.6 basis points at 4.21% and the 10-year rate rising 2.2 basis points to 4.56%.In company news, SK Hynix (SKHY, SKHYV) American depositary shares surged 13% in their Nasdaq debut on Friday. The stock opened traded at $170 and rose to as high as $177. The South Korean memory semiconductor company priced its initial public offering of 177.9 million ADS at $149 apiece.Meta Platforms (META) jumped 6%, the top gainer on the S&P 500. The Facebook parent is aiming to start the production of artificial intelligence chips from September, Reuters reported Thursday, citing an internal memo.Moderna (MRNA) was the worst performer on the S&P 500, down nearly 11%.Gold slipped 0.7% to $4,110.60 per troy ounce, while silver lost 1% to $60.17 per ounce.

Dow JonesNasdaq CompositeS&P 500$META$MRNA$SKHY$SKHYV
Update: Dow Logs Worst Day in 4 Weeks Amid Renewed US-Iran Tensions
US Markets

Update: Dow Logs Worst Day in 4 Weeks Amid Renewed US-Iran Tensions

(Updates with market moves at the end of the day and latest developments.)The Dow Jones Industrial Average logged its sharpest single-day decline in four weeks in a mixed session on Wednesday, as oil prices rallied after President Donald Trump warned of additional attacks on Iran.The Dow fell 1.1% to 52,348.4, its biggest percentage fall since June 10. The S&P 500 declined 0.3% to 7,482.7, while the Nasdaq Composite edged up 0.2% to 25,870.7. Barring energy and technology, all sectors were in the red led by materials.West Texas Intermediate crude oil was up 5.1% at $74.01 per barrel in Wednesday late-afternoon trade, while Brent jumped 5.8% to $78.46.During a North Atlantic Treaty Organization summit in Turkey on Wednesday, Trump said the memorandum of understanding signed with Iran last month to end the war in the Middle East was "over."The US struck Iran on Tuesday after Tehran attacked three tankers that crossed the Strait of Hormuz. Iran's Islamic Revolutionary Guard Corps hit US military targets across Bahrain and Kuwait in retaliation to Washington's attacks, CNN reported.Trump warned of more attacks on Iran."We hit them very hard last night," Trump said in Turkey. "We'll probably hit them hard again tonight."A peace deal between the US and Iran is a key risk to watch in the second half of 2026 as energy prices may determine inflation expectations, Oxford Economics Chief Global Economist Ryan Sweet said in remarks emailed to."If the peace deal breaks, and it's too early to tell, it won't just raise oil prices; it would also increase pressure on (artificial intelligence) supply chains in Asia, force central banks to be hawkish, tighten financial conditions, and could shift the outcome of the US midterms," Sweet said. "The cascade runs fast."US Treasury yields were higher, with the two-year rate increasing 4.4 basis points to 4.21% and the 10-year rate adding 4.2 basis points to 4.57%.Federal Reserve officials held diverging views last month on the appropriate path of interest rates, minutes from the central bank's June policy meeting showed Wednesday. At that meeting, the Federal Open Market Committee unanimously decided to maintain the policy rate steady for the fourth consecutive time."The June minutes put the focus on an uncertain balance of risks," TD Economics said in a report. "Participants agreed on holding rates steady in June, but not on whether the next move is more likely to be up or down, making future meetings more 'live' and dependent on incoming data."The International Monetary Fund lowered global economic growth expectations for 2026 as the impact of the Middle East war will likely counter a boost from rising artificial intelligence adoption.In company news, Apple (AAPL) said Wednesday that Broadcom (AVGO) will produce chips to be used in the iPhone maker' products in a deal likely worth more than $30 billion. Shares of Apple rose 0.9%, among the biggest gainers on the Dow, while Broadcom advanced 4.8%.Nvidia (NVDA) shares advanced 3.7%, the best performer on the Dow.Alibaba Group (BABA), ByteDance, and DeepSeek could receive permission from China to purchase a limited volume of Nvidia H200 chips to offset a shortage due to increasing demand for artificial intelligence chips, The Information reported Wednesday, citing sources with knowledge of the matter.Moderna (MRNA) slumped 7.5%, the second-worst performer on the S&P 500.Major US biopharmaceutical companies' performance in the second half of the year is likely to be driven largely by fundamentals as the focus shifts away from economic factors, Morgan Stanley said in a note.Gold shed 1.7% to $4,087.30 per troy ounce, while silver lost 4.2% to $58.75 per ounce.

Dow JonesNasdaq CompositeS&P 500$AAPL$AVGO$BABA$MRNA$NVDA
Japan

US Equity Markets Mixed After Trump Warns of Additional Strikes on Iran

US equity indexes closed mixed Wednesday after President Donald Trump warned of more strikes on Iran, though he said it wouldn't amount to a full-scale war, softening earlier comments suggesting the ceasefire with Tehran "is over."* Trump threatened Wednesday to unleash additional military strikes against Iran after saying Tehran's attacks on commercial ships signaled the end of the ceasefire, the Associated Press reported. He later said the most recent exchange of fire did not herald a return to full-scale war.* According to minutes released from Kevin Warsh's first meeting as Federal Reserve chairman in mid-June, policymakers are sharply divided on the future path of interest rates. Some anticipate that cooling inflation may allow cuts, while others warn that persistent price pressures might spur increases.* August West Texas Intermediate crude oil rose $3.78 to settle at $74.22 per barrel, while September Brent crude, the global benchmark, was last seen up $4.55 at $78.71.* Alibaba (BABA), ByteDance, and DeepSeek may receive permission from China to buy a limited volume of Nvidia (NVDA) H200 chips to offset a shortage of AI chips, The Information reported. Nvidia shares rose 3.7%, the biggest gain on the Dow Jones Industrial Average.* Major US biopharmaceutical companies' H2 performance is likely to be driven largely by fundamentals as the focus shifts away from economic factors, Morgan Stanley said. Moderna's (MRNA) shares slumped 7.5%, the second-biggest drop on the S&P 500.

Dow JonesNasdaq CompositeS&P 500$BABA$MRNA$NVDA
Update: Wall Street Falls Intraday as Trump Threatens to Hit Iran Again
US Markets

Update: Wall Street Falls Intraday as Trump Threatens to Hit Iran Again

(Updates with latest market prices and developments.)US stocks were lower intraday after President Donald Trump threatened additional attacks on Iran, sending oil prices sharply higher.The Dow Jones Industrial Average was down 1.2% at 52,311.4 after midday Wednesday, while the S&P 500 shed 0.4% to 7,473.7. The Nasdaq Composite edged down 0.1% to 25,784.6. Barring energy and technology, all sectors were in the red led by materials.West Texas Intermediate crude oil was up 5.9% at $74.59 per barrel intraday, while Brent jumped 6.5% to $78.99.During a North Atlantic Treaty Organization summit in Turkey on Wednesday, Trump said the memorandum of understanding signed with Iran last month to end the war in the Middle East was "over."The US struck Iran on Tuesday after Tehran attacked three tankers that crossed the Strait of Hormuz. Iran's Islamic Revolutionary Guard Corps hit US military targets across Bahrain and Kuwait in retaliation to Washington's attacks, CNN reported.Trump warned of more attacks on Iran."We hit them very hard last night," Trump said in Turkey. "We'll probably hit them hard again tonight.""The escalation threatens fragile negotiations aimed at securing a permanent peace, with both sides accusing the other of violating the ceasefire," Saxo Bank said in a report Wednesday. "Brent has moved back above $76, potentially triggering further short covering among hedge funds."US Treasury yields were higher intraday, with the two-year rate increasing 6.7 basis points to 4.23% and the 10-year rate adding 5.8 basis points to 4.59%.The Federal Reserve is scheduled to publish minutes of its June policy meeting at 2 pm ET, to be assessed for fresh insights on the central bank's monetary policy. At the meeting, policymakers kept their benchmark lending rate steady for a fourth consecutive time.The International Monetary Fund lowered global economic growth expectations for 2026 as the impact of the Middle East war will likely counter a boost from rising artificial intelligence adoption.In company news, Apple (AAPL) said Wednesday that Broadcom (AVGO) will produce chips to be used in the iPhone maker' products in a deal likely worth more than $30 billion. Shares of Apple were up 0.5%, among the biggest gainers on the Dow, while Broadcom advanced 5.9%, the second-best performer on the S&P 500.Moderna (MRNA) slumped 6.2%, the worst performer on the S&P 500.Major US biopharmaceutical companies' performance in the second half of the year is likely to be driven largely by fundamentals as the focus shifts away from economic factors, Morgan Stanley said in a note.Gold shed 2.5% to $4,066.8 per troy ounce, while silver lost 5% to $58.26 per ounce.

Dow JonesNasdaq CompositeS&P 500$AAPL$AVGO$MRNA
Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
US Markets

Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says

Major US biopharmaceutical companies' performance in the second half of the year is likely to be driven largely by fundamentals, as the focus shifts away from economic factors, Morgan Stanley said in a note e-mailed Wednesday.The investment firm revised its price targets for several biopharma stocks it covers ahead of the latest earnings season."The macro has been a key driver of large-cap biopharma performance over the first half of the year," the brokerage said in a note to clients. "Looking into the second half, we expect fundamentals to be more of a driver. We prefer stocks with upside from product cycles and/or pipeline catalysts."Morgan Stanley raised its price target for Eli Lilly (LLY) to $1,347 from $1,344. It expects second-quarter earnings per share of $9.06 for the pharmaceutical giant, compared with Wall Street's estimate of $8.80. The firm projects revenue of $20.78 billion, while the Street is looking for $20.47 billion.The firm expects Johnson & Johnson (JNJ) to deliver a second-quarter beat, with EPS projected at $2.90 and sales at $25.46 billion. Morgan Stanley raised its price target on the stock to $284 from $283.Pfizer's (PFE) second-quarter EPS is seen at $0.69, while the Street is looking for $0.68, according to the note. Revenue is projected at $14.29 billion, while the Street is eyeing $14.44 billion.Moderna's (MRNA) new price target is $39, up from $33 previously. The drugmaker is expected to report a second-quarter loss of $1.85 a share on revenue of $172 million versus the Street's views for a $2.06 loss and sales of $102 million, according to Morgan Stanley.The price target for the Abbvie (ABBV) stock moved to $279 from $278, with Morgan Stanley expecting the company's second-quarter revenue to be ahead of consensus and guidance at $16.88 billion, while EPS is seen at $3.71 versus the Street's forecast of $3.76.Morgan Stanley lowered its price target for Gilead Sciences (GILD) to $166 from $168. The brokerage is projecting a second-quarter loss per share at $7.34, while the Street is looking for a $7.31 loss. Revenue is expected at $7.36 billion, below the $7.41 billion consensus, according to the note.Price: $1228.54, Change: $-7.02, Percent Change: -0.57%

$ABBV$GILD$JNJ$LLY$MRNA$PFE
Wire

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday.As of July 6, the NYSE Arca Pharmaceutical Index has gained 11% and the Nasdaq Biotechnology Index has added 18%, compared with a 10% gain for the S&P 500 Index, with recent stock performance driven more by changes in valuation multiples than by earnings estimate revisions, the investment bank said.Morgan Stanley said its US Equity Strategy team expects the sector to benefit from broader market leadership. Biotech remains one of the most rate-sensitive sectors, and historically, the sector has delivered nearly 20% annualized returns during falling-rate environments, according to the note.In addition, merger and acquisition activity remains healthy, with several $5 billion to $10 billion deals recently announced, including AbbVie (ABBV) purchasing Apogee (APGE), and Vertex Pharmaceuticals (VRTX) buying Crinetics Pharmaceuticals (CRNX), the investment bank said.Morgan Stanley adjusted its price targets on Biogen (BIIB) to $222 from $224, Amgen (AMGN) to $333 from $340, Gilead Sciences (GILD) to $166 from $168, AbbVie to $279 from $278, Moderna (MRNA) to $39 from $33, BioNTech (BNTX) to $119 from $126, Regeneron Pharmaceuticals (REGN) to $730 from $788, Johnson & Johnson (JNJ) to $284 from $283, and Eli Lilly (LLY) to $1,347 from $1,344.Shares of Biogen, Amgen, Gilead, AbbVie, Moderna, BioNTech, Regeneron, Johnson & Johnson, and Eli Lilly were down 2%, 0.1%, 0.8%, 0.4%, 7%, 1.9%, 1.9%, 0.4%, and 0.5% respectively, in Wednesday trading.Price: $201.67, Change: $-4.03, Percent Change: -1.96%

$ABBV$AMGN$APGE$BIIB$BNTX$CRNX$GILD$JNJ$LLY$MRNA$REGN$VRTX
Japan

US Equity Markets End Lower Amid Technology Stocks Sell-Off

US equity indexes were lower on Friday amid a sell-off in technology stocks and despite a decline in crude oil prices following the Israel-Lebanon framework agreement.* Among stocks with a market capitalization of over $200 billion, 16 out of the 20 worst-performing stocks were technology firms.* The University of Michigan consumer sentiment index was revised up to 49.5 for June from 48.9 in the preliminary estimate, below expectations of 50.0 in a Bloomberg-compiled poll. The print was also above the final 44.8 in May.* August West Texas Intermediate crude oil fell $2.34 to settle at $69.58 per barrel, while August Brent crude, the global benchmark, was last seen down $3.05 at $72.21.* Moderna (MRNA) shares rose nearly 12%, the top gainer on the S&P 500, after the company said it plans to launch clinical development of in vivo CAR-T candidate mRNA-6007 in 2027. Multiple analysts also raised their price targets for the company.* Onsemi (ON) shares were down roughly 24%, the worst performer on the S&P 500, after the chipmaker agreed to acquire semiconductor company Synaptics (SYNA) in a deal valued at about $7 billion.

Dow JonesNasdaq CompositeS&P 500$MRNA$ON$SYNA
Wire

Piper Sandler Adjusts Price Target on Moderna to $77 From $69, Maintains Overweight Rating

Moderna (MRNA) has an average rating of hold and mean price target of $48.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $63.24, Change: $+3.49, Percent Change: +5.83%

$MRNA
Wire

Market Chatter: Moderna's Flu Shot Wins Support From FDA Advisers

Moderna's (MRNA) influenza vaccine for adults 50 and older received a recommendation for approval from outside advisers to the US Food and Drug Administration, Bloomberg reported Thursday, citing a unanimous vote by the agency's Vaccines and Related Biological Products Advisory Committee.The recommendation for the mRNA-based shot is nonbinding, though the FDA typically follows its advisory panels, the report said.Moderna did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $64.26, Change: $+2.46, Percent Change: +3.98%

$MRNA
Asia Markets

Update: US Equity Indexes Drop as Bets for Higher Interest Rates Jump After Fed Eliminates Easing Bias

(Updates with index/price moves, FedWatch outlook, macro data, and political/company news from the first paragraph.)US equity indexes fell while government bond yields jumped as odds favoring higher interest rates this year surged after the Federal Reserve removed the so-called easing bias from its policy statement.The Nasdaq Composite fell 1.4% to 26,021.66, with the S&P 500 down 1.2% to 7,420.10 and the Dow Jones Industrial Average lower by 1% to 51,492.55 on Wednesday. All sectors fell, with communication services, consumer discretionary, and consumer staples leading the decliners at the close.The Fed left its benchmark rate unchanged in the 3.50% to 3.75% range in a unanimous decision announced Wednesday, excluding language that suggested a lingering bias toward cuts."Economic activity is expanding at a solid pace despite elevated uncertainty that owes, in part, to the conflict in the Middle East," the Fed statement said. "Job gains have kept pace with the workforce, and the unemployment rate has changed little."The probability of a 25-basis-point increase in rates to a target range of 3.75% to 4% in July soared to 35% from 9% a day ago, according to the CME FedWatch tool. The comparisons for September were 47% versus 27%, and, for October, the data showed an increase to 45% from 33%. Strikingly, there is a 33% likelihood that rates will be 4% to 4.25% in December, implying that the Fed may raise rates by another 25 basis points even after tightening policy once between July and October.In economic news, retail sales climbed 0.9% after a downwardly revised 0.4% gain in April, the Census Bureau reported Wednesday. The consensus was for a 0.6% increase in May, based on a Bloomberg survey.Pending home sales rose by 3.8% in May, above the 0.9% increase expected in a survey compiled by Bloomberg and following a 0.3% increase in April, according to the National Association of Realtors. The monthly sales index was up 4.8% from a year ago.US Treasury yields jumped, with the 10-year surging 6.1 basis points to 4.49% and the two-year soaring 14.8 basis points to 4.2%.In geopolitical news, the US draft of the framework agreement with Iran includes a new 'minimum' standard for diluting Iran's uranium and toll-free passage of the Strait of Hormuz for 60 days, senior US officials told the Associated Press. That shows the US draft does not preclude Iran from imposing fees on maritime traffic after the fixed period.The US draft includes provisions to ensure "territorial integrity" of Lebanon after Israel's latest attacks in the country against the militant outfit Hezbollah, the officials were cited as saying. In return, the US will waive, but not eliminate, some sanctions that were previously imposed on Iran after the deal is signed on Friday, the news report said, adding that Tehran has not released its version of the peace deal.In his closing remarks at the G7 summit in France, French President Emmanuel Macron said that it is vital that Iran, Hezbollah, and Israel do not resume fighting, while noting that Paris supports a preliminary US-Iran deal to end the war, according to CNN.Front-month global benchmark North Sea Brent slipped 0.1% to $78.85 per barrel, and US West Texas Intermediate edged 0.2% lower to $75.92 per barrel.In company news, Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report published by German news outlet Handelsblatt. Shares of the COVID vaccine manufacturer soared 12%, the biggest outperformer on the S&P 500.

Dow JonesNasdaq CompositeS&P 500$MRNA
International

US Equity Markets End Lower After Government Bond Yields Rise, Fed's Policy Statement

US equity indexes were lower on Wednesday as government bond yields rose and the Federal Reserve announcement excluded any language hinting at near-term rate cuts.* "Economic activity is expanding at a solid pace despite elevated uncertainty that owes, in part, to the conflict in the Middle East," the Fed statement said. "Job gains have kept pace with the workforce, and the unemployment rate has changed little."* Iran accused Israel of violating the truce in Lebanon 84 times since it reached the interim agreement with the US and warned of a "harsh response" if attacks continue, Al Jazeera reported.* July West Texas Intermediate crude oil fell $0.10 to settle at $75.95 per barrel, while August Brent crude, the global benchmark, was last seen down $0.08 at $78.87.* Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares were up roughly 12%, the top gainer on the S&P 500, and BioNTech stock was up about 2.9%.* Carvana (CVNA) shares were down nearly 10%, the worst performer on the S&P 500, after competitor CarMax's (KMX) fiscal Q1 earnings fell year over year on Wednesday as comparable used vehicle sales swung negative and its management flagged higher margin pressure in the near term.

Dow JonesNasdaq CompositeS&P 500$BNTX$CVNA$KMX$MRNA
Sectors

Sector Update: Healthcare Stocks Retreat Late Afternoon

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.8%.The iShares Biotechnology ETF (IBB) rose 0.7%.In corporate news, ResMed (RMD) shares fell 4.5% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $230 from $286.UniQure (QURE) shares surged 76% after the company said that it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Novo shares were up 0.2%.Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares jumped almost 11%, and BioNTech was up 2.3%.

$BNTX$MRNA$NVO$QURE$RMD
Wire

Sector Update: Healthcare Stocks Decline Wednesday Afternoon

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index decreasing 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) rose 2.2%.In corporate news, IQVIA (IQV) shares fell 3.3% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $200 from $225.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Novo shares were up 1.8%.Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares jumped past 8%, and BioNTech was up 4%.

$BNTX$IQV$MRNA$NVO
International

US Equity Markets End Mixed as Dow Hits Record High Amid Lower Crude Oil Prices, Tech Stock Sell-Off

US equity indexes were mixed on Tuesday after the Dow Jones Industrial Average hit a new all-time intraday amid sliding crude oil prices, while technology stocks witnessed a sell-off.* Iran warned that any Israeli attack on Lebanon or continued occupation of its territory from now on will constitute a violation of the interim agreement with the US, Al Jazeera reported. However, Israeli Prime Minister Benjamin Netanyahu has made clear he does not intend to withdraw from southern Lebanon, Gaza, or Syria, according to the CNN news report.* US import prices jumped 1.9% in May, ahead of the 1% increase expected in a Bloomberg-compiled survey and following a 2.0% gain in April.* Redbook US same-store sales soared 9.4% from a year earlier in the week ended June 13, after surging 9.1% in the previous week.* July West Texas Intermediate crude oil fell $3.81 to settle at $76.94 per barrel, while August Brent crude, the global benchmark, was last seen down $3.47 at $79.70.* Moderna (MRNA) shares were up about 6.3%, the second-best gainer on the S&P 500, after the company said Tuesday it is changing the corporate operating model to support short and long-term business goals.* Marvell Technology (MRVL) shares fell nearly 10%, the steepest decline on the S&P 500, a day after outgoing CFO Willem Meintjes filed to sell 211,329 shares, according to Form 144 filings with the US Securities and Exchange Commission.

Dow JonesNasdaq CompositeS&P 500$MRNA$MRVL
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding about 0.7%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, West Pharmaceutical Services (WST) shares rose 3.1% after the company said it has restored its core enterprise systems following a recent cybersecurity attack.Eli Lilly (LLY) shares added 2.6% after the company said its investigational retatrutide delivered "clinically meaningful" weight loss in a phase 3 trial, where all doses met the primary and key secondary endpoints at 80 weeks.Hims & Hers Health (HIMS) said Thursday that it has launched generic semaglutide for eligible customers in Canada. Its shares gained 2.7%.Moderna's (MRNA) experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel on June 18, Bloomberg reported. Moderna shares were down 1.5%.

$HIMS$LLY$MRNA$WST
Sectors

Sector Update: Healthcare Stocks Rise Thursday Afternoon

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index increasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.5%.The iShares Biotechnology ETF (IBB) was up 0.6%.In corporate news, Eli Lilly (LLY) shares rose 2.1% after the company said its investigational retatrutide delivered "clinically meaningful" weight loss in a phase 3 trial, where all doses met the primary and key secondary endpoints at 80 weeks.Hims & Hers Health (HIMS) said Thursday that it has launched generic semaglutide for eligible customers in Canada. Its shares popped 3.3%.Moderna's (MRNA) experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel on June 18, Bloomberg reported. Moderna shares were down 1.5%.

$HIMS$LLY$MRNA
Wire

Market Chatter: Moderna's Experimental Flu Shot to Be Reviewed by FDA Panel in June

Moderna's (MRNA) experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel on June 18, Bloomberg reported Thursday, citing a notice.The FDA is expected to make a decision on whether to approve the vaccine by Aug. 5, the report said.Moderna didn't immediately reply to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $46.71, Change: $-1.42, Percent Change: -2.94%

$MRNA
Wire

Moderna's Experimental Flu Shot to be Reviewed by FDA Panel in June, Bloomberg Reports

Moderna's Experimental Flu Shot to be Reviewed by FDA Panel in June, Bloomberg Reports

$MRNA

Showing 1-20 of 48

Track with the FINWIRES app suite

MRNA News | FINWIRES